McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
McKesson (MCK) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
McKesson (MCK) reachead $488.78 at the closing of the latest trading day, reflecting a -1.95% change compared to its last close.
Here's Why McKesson (MCK) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
McKesson (MCK) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw McKesson (MCK) settling at $479.06, representing a -0.02% change from its previous close.
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson (MCK) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
The latest trading day saw McKesson (MCK) settling at $508, representing a -0.03% change from its previous close.
4 Stocks to Buy Amid Dental Supplies Industry Challenges
by Indrajit Bandyopadhyay
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA.
McKesson (MCK) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, McKesson (MCK) closed at $508.16, marking a -0.68% move from the previous day.
Here's Why You Should Retain McKesson Stock in Your Portfolio Now
by Zacks Equity Research
MCK's strategic collaborations and strength in Biologics raise optimism about the stock.
Top Stock Reports for Home Depot, Southern Company & Infosys
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), The Southern Company (SO) and Infosys Ltd. (INFY), as well as two micro-cap stocks Kewaunee Scientific Corp. (KEQU) and Friedman Industries, Inc. (FRD).
Why McKesson (MCK) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
McKesson (MCK) reachead $518.81 at the closing of the latest trading day, reflecting a +1.49% change compared to its last close.
McKesson (MCK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
McKesson (MCK) concluded the recent trading session at $511.17, signifying a +0.14% move from its prior day's close.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Shares Fall Following Sale of Rexall, Well.ca to Birch Hill
by Zacks Equity Research
MCK announces the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, aligning with its strategy to grow oncology and biopharma services.
Stock Market News for Sep 6, 2024
by Zacks Equity Research
Markets finished mixed on Thursday as soft economic data raised concerns of a recession and doubts about whether the Fed is behind the curve on interest rate cuts.
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson (MCK) Upgraded to Buy: Here's Why
by Zacks Equity Research
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
by Zacks Equity Research
Here is how Atea Pharmaceuticals, Inc. (AVIR) and McKesson (MCK) have performed compared to their sector so far this year.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See McKesson (MCK) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in McKesson (MCK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
by Zacks Equity Research
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Stock Gains 18% YTD: What's Driving the Rally?
by Harshit Gupta
McKesson's (MCK) shares rally on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to McKesson (MCK). This makes it worthwhile to examine what the stock has in store.